Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

By sjmartinez • November 6, 2022

Gong J, Thomassian S, Kim S, Gresham G, Moshayedi N, Ye JY, Yang JC, Jacobs JP, Lo S, Nissen N, Gaddam S, Tighiouart M, Osipov A, Hendifar A. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Nov 4;12(1):18731. doi: 10.1038/s41598-022-23619-6. Erratum for: Sci Rep. 2022 Sep 2;12(1):15013. PMID: 36333397; PMCID: PMC9636406.

Tags: General Internal Medicine, Publications

First comparison between artificial intelligence-guided coronary computed tomography angiography versus single-photon emission computed tomography testing for ischemia in clinical practice

Cho GW, Sayed S, D'Costa Z, Karlsberg DW, Karlsberg RP. First comparison between artificial intelligence-guided coronary computed tomography angiography versus single-photon emission computed tomography testing[...]

Inequities in Access to Mental Health Services Among Asian American, Native Hawaiian, and Pacific Islander Medicaid Enrollees

Nguyen KH, Oh EG, Ðoàn LN, Chu CT, Banawa RA, Oronce CIA, Choy CC, Zhou S. Inequities in Access to Mental Health Services Among Asian[...]

Increasing Diversity in the Nutrition, Obesity, and Diabetes Biomedical Workforce: The BRIDGES Consortium

Newton RL Jr, Katzmarzyk PT, Duru OK, Lee A, Irwin A, Mangione CM, Morone NE, Ongeri EM, Shaikh SR, Stanford FC, Stanley TL, Truesdale KP;[...]